Researchers at the Institute for Molecular Bioscience (IMB) at The University of Queensland (UQ) have initiated a research program to resurrect the antibiotic fruilimicin B that displays broad spectrum activity against a variety of gram positive bacteria. Unlike daptomycin, friulimicin B maintains activity in the presence of pulmonary lung surfactant, which opens the possibility for use in treatment of Gram-positive lung infections. Friulimicin B represents a new MoA for human antibiotics that involves the complexation of undecaprenyl phosphate (C55-P), which interferes with both peptidoglycan and teichoic acid biosynthesis.

UniQuest Contact: 

Mark Ashton

Position: 
Executive Director, Intellectual Property Commercialisation
Mobile phone: 
+61 410 601 970
Work phone: 
+61 (7) 3365 4037